financetom
Business
financetom
/
Business
/
Update: Endeavour Silver Jumps 18% as Q4 Adjusted Earnings Beat Analysts' Estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Endeavour Silver Jumps 18% as Q4 Adjusted Earnings Beat Analysts' Estimates
Mar 11, 2025 9:41 AM

12:17 PM EDT, 03/11/2025 (MT Newswires) -- (Updates shares.)

Endeavour Silver ( EXK ) was last seen up 18% as the company beat analysts' adjusted earnings expectations for the fourth quarter.

The company booked adjusted earnings, excluding most one-time items, of US$4.8 million, or US$0.02 per share, beating the analyst consensus loss per share forecast of US$0.01 compiled by FactSet, and rising from US$3.3 million, or US$0.02 per share, posted a year ago.

Revenue fell 16% to US$42.2 million, below the analyst sales forecast of US$47.5 million compiled by FactSet.

Silver equivalent production sank 29% to 1.55 million ounces.

"The company achieved strong financial results in 2024, maintaining a solid balance sheet," chief executive Dan Dickson said. "With the Terronera project nearing completion and Pitarrilla progressing toward an economic assessment, we are well-positioned for sustained growth and value creation."

Endeavour Silver ( EXK ) shares were last seen up $0.96 to $6.19 on the Toronto Stock Exchange.

Price: 6.20, Change: +0.97, Percent Change: +18.55

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints
Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints
Jun 17, 2024
07:59 AM EDT, 06/17/2024 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) said Monday its phase 3 trials evaluating soticlestat to treat refractory Dravet syndrome and Lennox-Gastaut syndrome missed the primary endpoints. The study evaluating soticlestat in participants with Dravet syndrome narrowly missed the primary endpoint of reduction from baseline in convulsive seizure frequency compared to placebo, while the study...
NuVista Energy Gets TSX Approval for Renewal of Normal Course Issuer Bid
NuVista Energy Gets TSX Approval for Renewal of Normal Course Issuer Bid
Jun 17, 2024
07:54 AM EDT, 06/17/2024 (MT Newswires) -- NuVista Energy ( NUVSF ) on Monday said the TSX approved the renewal of its normal course issuer bid, allowing it to repurchase up to 14.2 million common shares. The normal course issuer bid will become effective on Wednesday and will terminate on June 18, 2025, or when it is completed or terminated...
Almaden Minerals Initiates Arbitration Proceedings Against Mexico at International Centre for Settlement of Investment Disputes
Almaden Minerals Initiates Arbitration Proceedings Against Mexico at International Centre for Settlement of Investment Disputes
Jun 17, 2024
07:50 AM EDT, 06/17/2024 (MT Newswires) -- Almaden Minerals ( AAUAF ) said on Monday that it has initiated international arbitration proceedings against Mexico at the International Centre for Settlement of Investment Disputes The company contends that Mexico breached its obligations by allegedly taking steps that blocked the development of the Ixtaca project. Almaden also alleges that Mexico retroactively terminated...
Top Premarket Gainers
Top Premarket Gainers
Jun 17, 2024
07:45 AM EDT, 06/17/2024 (MT Newswires) -- Scinai Immunotherapeutics ( SCNI ) shares surged 94% Monday premarket, extending Friday's rally. The Aaron's Company (AAN) shares advanced 31% after the company agreed to a takeover offer from IQVentures. Nurix Therapeutics ( NRIX ) shares were up 13% after the company said Sunday that patients responded well to its treatment candidate for...
Copyright 2023-2026 - www.financetom.com All Rights Reserved